This measure identifies adult patients with a diagnosis of rheumatoid arthritis who received appropriate baseline complete blood count (CBC) testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide during the measurement year.
-
-
1.5 Measure Type1.7 Electronic Clinical Quality Measure (eCQM)1.8 Level Of Analysis1.9 Care Setting1.20 Testing Data Sources
-
1.14 Numerator
Patients in the denominator who received CBC testing within 90 days before to 14 days after the new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide.
-
1.15 Denominator
Patients >=18 years old with a history of rheumatoid arthritis and a new start of sulfasalazine, methotrexate, leflunomide, azathioprine, D-Penicillamine, intramuscular gold, oral gold, cyclosporine, or cyclophosphamide anytime from the beginning of the measurement year to 14 days prior to the end of the measurement year. (This list of DMARDs will hereafter be referred to as ´DMARD needing baseline CBC´ )
-
Exclusions
The measure excludes patients who have had an inpatient hospitalization during the measurement year because UB04 claims do not document individual lab tests ordered during an inpatient stay.
-
Most Recent Endorsement ActivityMeasure Retired and Endorsement Removed Musculoskeletal Endorsement Maintenance ProjectInitial EndorsementLast UpdatedRemoval Date
-
StewardSteward Organization Email
-
-
-
Risk Adjustment
-
-
-
6.1.2 Current or Planned Use(s)6.1.3 Current Use(s)
-